Investigating CAR T-Cell Therapy Wait Time and High-Risk Disease Definitions in Myeloma With Samer Al Hadidi, MD, MS, FACP

At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  

Continue reading

Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD

In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.

Continue reading

Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD

At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  

Continue reading

Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  

Continue reading

Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD

Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about wh...

Continue reading

Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS

At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.  

Continue reading

Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD

Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation. This podcast episode was recorded live by O...

Continue reading

Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD

Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 

Continue reading

Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD

At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).  

Continue reading

Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD

In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of Acute B-Cell Leukemia: An Evolving Treatment Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.

Continue reading

Additional Advances in Chemotherapy-Induced Neutropenia Research and Clinical Trials

Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  

Continue reading

Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD

In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them. 

Continue reading

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD

Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.

Continue reading

Pioneering the Field of Stem Cell Biology With Irving Weissman, MD

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  

Continue reading

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 

Continue reading

Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials With Morie Gertz, MD

In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.

Continue reading

Pioneering the Field of Stem Cell Biology With Irving Weissman, MD

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  

Continue reading

Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD

Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares the four abstracts which he believes will have the grea...

Continue reading

Oncology Data Advisor 2022 Year-End Wrap-Up

Wow! 2022 has been an exciting year of new challenges, amazing successes, and incredible opportunities. And we couldn't have gotten through it all without YOU! Before we wrap up the top stories and new features from OncData this year, we want to take time to thank each and every one of YOU: doctors, nurses, medical staff, and all frontline workers for your continued dedication. You continue to inspire us each and every day. THANK YOU!

Continue reading

CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.